Transcript

Ep 39 - The GLP-1 Gold Rush: Weight-Loss Drugs Rewire Big Business · The Business Briefing: Global Markets & Money

HOST: One class of weight-loss drugs is now big enough to move stock markets, scare snack companies, and rewrite healthcare budgets. [SFX: surprise whoosh] HOST: GLP-1 medicines, including Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, are no longer niche diabetes treatments. They’re becoming consumer blockbusters. Analysts at Goldman Sachs have estimated the obesity-drug market could reach 100 billion dollars a year by 2030. HOST: That explains the land grab. Lilly is pouring billions into new manufacturing sites. Novo Nordisk became Europe’s most valuable company, at times bigger than the entire Danish economy’s annual output. [AD_BREAK:1] HOST: But here’s the twist: the impact doesn’t stop at pharma. Walmart executives have said shoppers using these drugs may buy slightly less food. Investors immediately started asking what happens to soda, chips, fast food, and even airlines if passengers get lighter. [SFX: confused beep] HOST: Insurers face the hardest math. These drugs can cost over 1,000 dollars a month in the U.S. Cover them widely, and budgets explode. Don’t cover them, and long-term obesity-related costs keep rising. [AD_BREAK:2] HOST: Next up is competition: pills, cheaper biosimilars, and government price pressure. The winners won’t just sell medicine. They’ll control supply, data, reimbursement, and trust. HOST: This isn’t just a health trend. It’s a balance-sheet revolution in a syringe.